Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* men \> 18 and ≤ 75 years~* post-menopausal women ≤ 75 years (follicle stimulating hormone (FSH) \>30 mIU/ml, women \> 60 years FSH \> 20 mIU/ml )~* well controlled diabetes mellitus type II (glycohaemoglobin ≤ 8,0 %)~* LDL-cholesterol ≤ 160 mg/dl~* LDL-subfractions: concentration of apoB-100 in dLDL (LDL-5 und LDL-6) \> 25 mg/dl~* written informed consent~Exclusion Criteria:~* participation in a clinical trial within the last 30 d before screening- visit~* patient is unable to give written informed consent~* Body mass index \<15 kg/m² and \> 35 kg/m²~* clinical atherosclerotic disease (coronary heart disease, peripheral artery disease, carotid artery disease)~* malignoma~* uncontrolled arterial hypertension (\>160/\>100 mmHg)~* clinically relevant disease of liver and/or kidneys~* clinically relevant endocrinally or hematologic problems~* allergy to study medication (Ezetimibe and/or Simvastatin)~* alcohol- or drug abuse~* laboratory: alanine aminotransferase, aspartate aminotransferase, total bilirubin \> 3 x ULN, creatine kinase \> 5 x ULN~* Concurrent treatment with potent CYP3A4-inhibitors (e.g. itraconazole, ketoconazole, HIV-protease-inhibitors, erythromycin, clarithromycin, telithromycin und nefazodone)~* other relevant diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10mg/d (Type: ACTIVE_COMPARATOR): intake of ezetimibe 10mg per day for six weeks after wash-out
- Simvastatin 20 mg per day (Type: ACTIVE_COMPARATOR): intake of simvastatin 20 mg per day for six weeks after wash-out
- Ezetimibe 10 mg/d and Simvastatin 20mg/d (Type: ACTIVE_COMPARATOR): intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out

Based on this trial design, predict the completion outcome and termination type (if applicable).